Cellular Biomedicine Group,
a biopharma firm engaged in the development of treatments for degenerative and cancerous diseases, plans to expand into the China Osteoarthritis and Rheumatoid Arthritis market. Following a complete analysis of current China patents by an intellectual property law firm, Cellular Biomedicine Group has clearance to pursue IP operation with respect to its patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.
Dr. Wei (William) Cao, president of Cellular Biomedicine Group, said, "In China there are 72.5 million people suffering from knee osteoarthritis (KOA), and 4.5 million suffering from rheumatoid arthritis (RA). We are very confident to enter the world's largest KOA and RA market with freedom of operation."